BioSpace News Archive

Aytu BioPharma, Inc. announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A (UVA) light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy.

Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the development of a new comprehensive digital tool designed to arm clinicians with the data and insights they need to better manage breathing for critically ill patients.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced key clinical data from the virtual 81st annual American Diabetes Association Scientific Sessions.

Shoreline Biosciences, Inc. today announced the appointment of Mohammad El-Kalay , Ph.D., as Senior VP and Head of CMC

Cosmos Holdings, Inc. is pleased to announce that Mr. Greg Siokas, Chief Executive Officer, has reduced the debt of the Company by converting $3.0 million of related party debt personally owed to him in exchange for 500,000 shares of common stock at $6.00 per share on June 25, 2021.

ImmunityBio and NantOmics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive T cells from individual patients.

MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (“MYM” or the “Company”) is pleased to announce that both Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”), the two leading independent proxy advisory firms that provide voting recommendations to shareholders, have each issued positive reviews of the proposed acquisition of MYM by IM Cannabis Corp. (“IMCC”) announced on April 1, 2021 (the “Transaction”)

Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

Angel Medical Systems, Inc., (dba AngelMed) a proactive diagnostics company focused on the advancement of long-term management of high-risk coronary disease, announced today the FDA approval of the second-generation AngelMed Guardian® device.

Vorticom was engaged for an initial term of two years on January 16, 2019, which was extended effective September 1, 2020, for a successive 12-month period.